Stockwinners Market Radar for June 21, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:04 EDT Verve Therapeutics CEO buys 2.5K shaes, Chief Scientific Officer buys 5K shares - In two separate regulatory filings, Verve Therapeutics disclosed that its CEO Sekar Kathiresan bought 2.5K shares of common stock for $47.5K and Chief Scientific Officer Andrew Bellinger bought 5K shares of common stock for $95K on June 21st.

18:18 EDT Microsoft's Xbox taps Kim Swift to help build video games for the cloud - Microsoft's Xbox Game Studios Publishing announced that Kim Swift, who worked on the "Portal" video game franchise, is joining the company to "accelerate its innovation" and collaborate with independent studios to build games for the cloud. "Our team focuses on three pillars in our games: Community, Innovation and Inclusivity," XGS Publishing said on Twitter. Reference Link

17:59 EDT TikTok enhances experience with new content integrations with 'Jump' - Sean Kim, Head of Product, TikTok US said in a blog posting, in part: "Today we're excited to introduce TikTok Jump, a new way for creators to share engaging and informative content on TikTok. Built by third-party providers, Jumps are mini-programs and services that creators can link to within their videos. Users around the world can click these links to explore recipes, take quizzes, discover useful learning tools and much more, creating more dynamic and practical experiences for our community." Publicly traded companies that compete with TikTok include Snap (SNAP), Facebook (DB) and Twitter (TWTR). Reference Link

17:16 EDT Lockheed Martin awarded $472.47M Navy contract modification - Lockheed Martin awarded a not-to-exceed $472.47M undefinitized contract modification to a previously awarded cost-plus-incentive-fee contract. This modification adds scope to further develop and integrate three unique weapons capabilities through system functional review to development test complete on the F-35A and F-35B aircraft for the governments of the United Kingdom and Italy. Work is expected to be completed in March 2026. Non-Department of Defense participant funds in the amount of $116.46M will be obligated at time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:14 EDT Dell and Insight awarded $155.3M, $161.5M Navy contracts respectively - Dell (DELL) was awarded an estimated $155.3M and Insight (NSIT) was being awarded an estimated $161.5M, short-term, single-award, firm-fixed-price blanket purchase agreement under the Department of Defense Enterprise Software Initiative, or DoD ESI, in accordance with Defense Federal Acquisition Regulation System 208.74. The DoD ESI streamlines software licensing acquisition and provides information technology products that are compliant with DoD technical standards and represent the best value for the DoD. This agreement will provide commercially available perpetual licenses, software assurance, user-based subscription licenses to include Microsoft 365 (MSFT), Microsoft Azure and client access licenses among others. This agreement will be used by the Department of Navy to include the Marine Corp and Coast Guard when authorized under the provisions of 14 U.S. Code Section 3 and Section 145; 10 U.S.C. Section 2571; and 31 U.S.C. Section 1535. The total value of this award is $316.8M. The ordering period will be for a total of six months from June 17, through December 16. This agreement will not obligate funds at the time of award. Funds will be obligated via delivery orders using operation and maintenance funds. Future requirements will be procured in accordance with DFAR 8.405-3. This action was sole-sourced under the authority of DFAR 8.405-6 urgent and compelling. Naval Information Warfare Center Pacific is the contracting activity.

17:08 EDT Boeing awarded $169.46M Army contract - Boeing was awarded a $169.46M firm-fixed-price contract to support the Apache full-rate production Lot 12 long lead effort. Bids were solicited via the internet with one received. Work will be performed in Mesa, Arizona, with an estimated completion date of May 31, 2027. FY21 aircraft procurement funds in the amount of $169.46M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

16:53 EDT PennantPark Floating Rate names Richard Cheung as CFO - PennantPark Floating Rate Capital announced that it has appointed Richard Cheung as its CFO and Treasurer, effective June 21. Cheung most recently served as Senior Managing Director and Head of Alternative Investment Accounting at Guggenheim Partners. Aviv Efrat, PFLT's current CFO and Treasurer, will move within the PennantPark organization and remain in senior management where he will focus on PennantPark's strategic growth initiatives.

16:42 EDT Forum Merger III management team purchases $4.9M of company stock - Forum Merger III (FIII) and Electric Last Mile (ELMS) announced that Forum's management team purchased approximately $4.9M, or 500,000 shares, of Forum's common stock on the open market. Forum will hold a special meeting of its stockholders on June 24 to approve its proposed business combination with ELMS. If the business combination is approved, the combined company will be named Electric Last Mile Solutions and the common stock of Electric Last Mile Solutions will continue to be listed on the Nasdaq Capital Market under the new ticker symbol "ELMS."

16:39 EDT O'Reilly Automotive director Lawrence O'Reilly sells almost $12M in shares - O'Reilly Automotive director Lawrence O'Reilly disclosed in a filing that he had sold 22,053 shares of company stock at $534.24 per share on June 17, for a total transaction amount of $11,781,584.

16:34 EDT Capital Senior Living announces May occupancy of 78.2% - Capital Senior Living announced its May occupancy of 78.2%, which is an increase of 294 basis points from the pandemic low average monthly occupancy of 75.3% in February. Approximately 53% of its 60 owned communities and all but two of its managed communities are above pre-pandemic February 2020 occupancy levels. "The positive occupancy trends are very encouraging as we enter the growth-focused phase of our strategic plan," said Kimberly S. Lody, President and CEO. "We attribute this increase in occupancy to several factors - the safety protocols we implemented at the onset of the pandemic, our well-executed vaccination program that has allowed us to ease restrictions across much of our portfolio and the introduction of new resident-centric programming."

16:31 EDT Tupperware Brands announces $250M share repurchase plan - Tupperware announced the prepayment of $58M of its Term Loan Debt from Angelo Gordon and JP Morgan, and, that its Board of Directors has authorized share repurchases of up to $250M of the company's outstanding shares of common stock.

16:21 EDT Genuine Parts names Naveen Krishna Chief Information & Digital Officer - Genuine Parts Company (GPC) announced that Naveen Krishna has joined the company as Executive Vice President and Chief Information & Digital Officer. In this key leadership role, Krishna has responsibility for leading the strategy and direction for all technology and digital initiatives and ensuring alignment with GPC's strategic roadmap. He will report to Will Stengel, President. Krishna joins GPC with more than 25 years of technology experience, primarily in the omni-channel retail and consumer products industries. Most recently, he was Executive Vice President and Chief Technology and Information Officer for Macy's (M).

16:19 EDT Corporate Office Properties executes pre-leases at Redstone Gateway - Corporate Office Properties Trust executed two leases totaling 178,500 square feet at Redstone Gateway with a defense contractor that provides information assurance, enterprise solutions, and technology modernization services to the U.S. Government. The defense contractor will consolidate from multiple existing Huntsville facilities into two new developments COPT will construct for $65M. The defense contractor will occupy 90% of a 172,500 square foot office building and roughly half of a 45,000 square foot R&D facility. Both projects are scheduled for shell completion in the fourth quarter of 2022, with lease commencement dates expected in the first quarter of 2023.

16:18 EDT Sonoco Products implements $50 per ton price increase for URB - Sonoco announced it is implementing a $50 per ton price increase for all grades of uncoated recycled paperboard, or URB, in the United States and Canada, effective with shipments beginning July 15. Sonoco said the price increase was in response to continuing strong demand across its U.S. and Canada mill network which has driven order backlogs to near historical levels as well as stepped up inflationary pressures from energy, freight, papermaking chemicals and packaging materials.

16:10 EDT Shoe Carnival announces two-for-one stock split - Shoe Carnival announced that its board has authorized a two-for-one stock split of the company's common stock. The stock split will be effected by the payment of a stock dividend of one share on each share of common stock to shareholders of record at the close of business on Tuesday, July 6, 2021.

16:09 EDT Sanderson Farms jumps after WSJ says exploring sale - Shares of Sanderson Farms (SAFM) are up 7% to $178 in after-hours trading after the Wall Street Journal reported that the company hired Centerview Partners to explore a potential sale and has attracted interest from suitors including agricultural investment firm Continental Grain Co. Other publicly traded companies in the meat space include Hormel Foods (HRL), Pilgrim's Pride (PPC) and Tyson Foods (TSN).

16:08 EDT Inhibrx initiates potential registration-enabling Phase 2 study of INBRX-109 - Inhibrx announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma. A randomized, blinded, placebo-controlled, potential registration-enabling Phase 2 trial of INBRX-109 in conventional chondrosarcoma initiated this month. The primary objective of this trial is to evaluate the anticancer efficacy of INBRX-109, as measured by PFS per RECISTv1.1 and assessed by central independent radiology review. Patients with disease progression on placebo will be able to crossover to INBRX-109. An interim analysis will occur after 50% of the planned PFS events are observed. Additionally, upon initiation of this study, Inhibrx's loan agreement with Oxford Finance was amended and $40M in additional principal was received by Inhibrx on June 18.

16:08 EDT CrossFirst Bankshares names Ben Clouse CFO - CrossFirst Bankshares (CFB) announced that it has named Ben Clouse as Chief Financial Officer. In the CFO role, Clouse will lead the financial organization and be responsible for overall long-range financial planning and reporting as well as support execution of the bank's growth strategy. "After conducting a thorough nationwide search, we are pleased to have found the ideal CFO candidate right here in Kansas City," said President & CEO of CrossFirst Mike Maddox. "Ben has deep and extensive experience in leading financial operations as well as driving operational change, including as the Chief Financial Officer of a publicly-traded company. He will be a key part of our executive leadership team and I know will be instrumental in helping us to continue to grow strategically as well as meet the evolving and changing needs of our clients." Prior to joining CrossFirst, Clouse was CFO of Waddell & Reed (WDR).

16:07 EDT Crown Electrokinetics names Joel Krutz as CFO, succeeding Phil Anderson - Crown Electrokinetics (CRKN) announced the appointment of Joel Krutz as CFO, effective June 21. Krutz succeeds Phil Anderson, who has decided to pursue new opportunities after successfully leading Crown through key capital raises and an uplisting. Most recently, Krutz had served as CFO for ViacomCBS Networks International (VIAC), the premium content companies international division since 2015.

16:06 EDT NextGen Healthcare CEO Rusty Frantz to step down - The company states: "NextGen Healthcare announced that the company and Rusty Frantz have agreed to a mutual separation and that Mr. Frantz will no longer serve as President, CEO or a member of the NextGen Healthcare Board of Directors, effective immediately. An Executive Leadership Committee has been established to lead NextGen Healthcare on an interim basis while its next CEO is identified with the assistance of executive search firm Spencer Stuart."

16:03 EDT Nurix Therapeutics appoints Stefani Wolff as COO - Nurix Therapeutics announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product development. Ms. Wolff brings to Nurix over 30 years of leadership experience in oncology and immunology most recently from Principia Biopharma Inc., where she served as chief development officer and formerly senior vice president of strategy and operations overseeing Principia's portfolio including BTK targeted agents. During her tenure at Principia, she successfully guided drug pipeline strategy and led many functions over time, including the company's manufacturing and technical operations, regulatory and quality, clinical operations, project and portfolio management, medical affairs, commercial and communications functions until its acquisition by Sanofi in September, 2020.

16:01 EDT Taylor Morrison announces CFO Dave Cone to retire - Taylor Morrison Home announced that Dave Cone, Executive Vice President and CFO, intends to retire from the company. Cone's retirement is expected to occur later this year once a successor has been named. The company has engaged Russell Reynolds Associates, a national executive search firm, to conduct an external search to identify Cone's replacement, in addition to internal candidates.

14:57 EDT Representative Jordan requests competition information from Microsoft - U.S. Representative Jim Jordan, a Republican from Ohio, is calling on Microsoft (MSFT) to face similar antitrust scrutiny as other major tech companies, including Apple (AAPL), Amazon (AMZN), Facebook (FB), and Google (GOOGL), according to a letter Jordan sent to Microsoft president Brad Smith. "Big Tech, including Microsoft, Inc., is out to get conservatives," Jordan wrote in the letter. "Despite Microsoft's size and market dominance, House Democrats curiously did not significantly examine Microsoft's conduct during their investigation of competition in digital markets. Democrats also seem to have excluded Microsoft from scrutiny in their large package of bills to radically rewrite American antitrust law. We write to request more information about these matters." Reference Link

13:21 EDT Uber to buy remaining 47% stake in grocery delivery start-up Cornershop - In an earlier regulatory filing, Uber said it was acquiring the remaining 47% share in grocery delivery start-up Cornershop. Uber said: "On June 18, Uber Technologies reached an agreement with the minority shareholders of Cornershop to acquire their interests in Cornershop in an all-stock transaction following which Cornershop will become a wholly-owned subsidiary of the Company. Uber acquired a majority stake in Cornershop in Q3 2020, other than in Mexico, which closed in January. With this transaction, the Company is acquiring the remaining approximately 47% interest in exchange for approximately 29M shares of the Company . The transaction is subject to customary closing conditions and is expected to close in July 2021. Cornershop's financial results are already fully consolidated in the Company's financial statements given the Company's existing majority ownership, therefore no change is expected to the Company's Gross Bookings, Revenue or Adjusted EBITDA as a result of the transaction." Reference Link

12:07 EDT Verizon announces acquisition of precise positioning company Senion - Verizon announced the acquisition of Senion, the developer of an indoor positioning platform. "Senion's advanced machine-learning sensor fusion technology delivers sub-meter accuracy for precise positioning and navigation of indoor spaces. Senion's employees have joined the Location Technology team within Verizon New Business Incubation, whose mission is to scale new automation businesses, fueled by the inherent orchestration power of 5G," Verizon stated. Reference Link

12:00 EDT Azure Power falls -11.2% - Azure Power is down -11.2%, or -$2.89 to $22.94.

12:00 EDT AiHuiShou falls -19.4% - AiHuiShou is down -19.4%, or -$3.34 to $13.87.

12:00 EDT Figs rises 12.6% - Figs is up 12.6%, or $4.58 to $40.98.

11:23 EDT CD Projekt's 'Cyberpunk 2077' available on PS Store after December removal - Sony's (SONY) PlayStation Twitter account said that CD Projekt's (OTGLY) "Cyberpunk 2077" is now available at PlayStation Store. Work on the PS4 version continues, with fixes and updates to be released throughout the year, Sony said. For the best experience on PlayStation, playing on PS4 Pro or PS5 consoles is recommended, the company added. The Fly notes that "Cyberpunk" was removed from the PS Store shortly after its December 2020 release as the game launched with a litany of bugs, glitches, and other technical shortcomings. Reference Link

11:03 EDT Intel announces new additions to product portfolio for 5G and edge - Intel showcased "multiple groundbreaking network deployments powered by its technology" and unveiled the Intel Network Platform today as part of its MWC 2021 virtual event, the company announced. Intel also announced new additions to its "leading product portfolio" for 5G and edge, that it said reaffirms its "position as the leading network silicon provider." The company noted that "nearly all" commercial virtual radio access network, or vRAN, deployments are running on Intel technology. In the years ahead, it sees global vRAN base station deployments scale, from hundreds to "hundreds of thousands," and eventually millions, Intel added.

11:02 EDT Frontdoor appoints Tony Bacos as SVP, chief digital officer - Frontdoor (FTDR) announced that Tony Bacos has joined the company as its first senior vice president and chief digital officer. This is a new role for Frontdoor. In this role, Bacos will be responsible for the strategy and execution of technology initiatives and investments across the organization. This role will play a critical part in Frontdoor's continued transformation and will include crafting the vision for future technology and shepherding the company's engineering, product management, data science, machine learning, user experience, data security and corporate technology teams. Bacos recently served as vice president and chief technology officer for Amazon Fashion (AMZN).

10:32 EDT Supreme Courts sends shareholder suit against Goldman back for more proceedings - Shareholders have filed a securities-fraud class action alleging that The Goldman Sachs Group and certain of its executives violated securities laws and regulations prohibiting material misrepresentations and omissions in connection with the sale of securities, noted the Supreme Court in a ruling posted to its site. The Second Circuit authorized an appeal under Federal Rule of Civil Procedure 23(f), and affirmed in a divided decision, finding that the District Court's price impact determination was not an abuse of discretion. Goldman has argued that the Second Circuit erred twice: first, by holding that the generic nature of Goldman's alleged misrepresentations is irrelevant to the price impact inquiry; and second, by assigning Goldman the burden of persuasion to prove a lack of price impact. In its own decision, the Supreme Court held some of the prior rulings, vacated some of the prior rulings and remanded the case for further proceedings. Reference Link

10:00 EDT BIT Mining Limited falls -8.8% - BIT Mining Limited is down -8.8%, or -83c to $8.64.

10:00 EDT AiHuiShou falls -12.7% - AiHuiShou is down -12.7%, or -$2.19 to $15.02.

10:00 EDT Dynagas LNG rises 13.2% - Dynagas LNG is up 13.2%, or 37c to $3.18.

09:47 EDT Korea Electric Power falls -5.3% - Korea Electric Power is down -5.3%, or -62c to $11.02.

09:47 EDT BIT Mining Limited falls -11.5% - BIT Mining Limited is down -11.5%, or -$1.09 to $8.38.

09:47 EDT ZipRecruiter rises 6.3% - ZipRecruiter is up 6.3%, or $1.33 to $22.59.

09:45 EDT Gold Royalty Corp trading resumes

09:35 EDT Ocugen appoints Ken Inchausti as head, investor relations & communications - Ocugen announced that Ken Inchausti has joined the company as Head, Investor Relations & Communications. Mr. Inchausti will oversee the company's investor relations activities, corporate communications and strategic positioning, leading issues management strategy and proactive media and social media relations programming. Inchausti joins Ocugen from Novo Nordisk Inc., where he was Senior Director, Reputation & Brand, leading corporate media relations, executive visibility, reputation strategy and research, crisis and issues management and corporate communications for the US affiliate.

09:33 EDT Theratechnologies announces preclinical findings for TH1902 - Theratechnologies announced new preclinical in vivo findings on the anti-metastatic effect and tolerability of its novel investigational proprietary peptide-drug conjugate, TH1902. These results demonstrate that TH1902 has better anti-metastatic activity when compared to docetaxel alone when administered at an equimolar concentration in a lung metastasis cancer model expressing the sortilin receptor. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. It is well-known that the survival rate for metastatic cancer is low. The Company intends to present these findings at an upcoming scientific meeting.

09:31 EDT Genius Brands appoints Cynthia Turner-Graham to board of directors - Genius Brands International announced the appointment of Dr. Cynthia Turner-Graham to the Company's Board of Directors. Cynthia Turner-Graham, MD, is a board-certified psychiatrist and Distinguished Life Fellow of the American Psychiatric Association, who brings over 40 years of experience in the healthcare industry as a practicing psychiatrist, healthcare administrator and community leader.

09:31 EDT Brazil Minerals to begin lithium drilling campaign - Brazil Minerals announced that plans are underway to begin its first lithium drilling campaign in its hard-rock lithium project in northern Minas Gerais. The area to be drilled is known to contain spodumene and lepidolite, both lithium-bearing minerals. This initial drilling campaign will entail at least six drill holes with completion in the third quarter of 2021. It is expected that the results of this campaign will allow for an initial technical report with estimation of lithium grade and mineralization volume.

09:29 EDT Privia Health to be added to Russell 2000 Index - Privia Health Group announced that it is set to join the Russell 2000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021.

09:29 EDT Rackspace Technology spearheads digital transformation for BFC Group - Rackspace Technology has announced that BFC Group Holdings is shifting its core application and supporting systems to Amazon Web Services. The migration creates a robust platform for BFC to focus on delivering seamless financial services to customers without the complexity of managing and maintaining a vast data centre. Rackspace Technology has helped BFC migrate its core application and supporting systems to the AWS public cloud while providing ongoing management and consultancy services.

09:26 EDT Simon Property board increases quarterly dividend 7.7% to $1.40 per share - Simon, a global leader in the ownership of premier shopping, dining, entertainment and mixed-use destinations, today announced a 7.7% increase in its common stock dividend for the second quarter 2021. Simon's Board of Directors has declared a $1.40 per common share dividend, payable in cash, for the second quarter 2021. The dividend will be payable on July 23, 2021 to shareholders of record at the close of business on July 2, 2021.

09:24 EDT STMicroelectronics announces solution for Qi-certfied chargers - STMicroelectronics is protecting wireless charging of small devices and mobiles with a convenient solution for authenticating certified Qi chargers. Wireless charging, enabled on an increasing variety of smartphones and wearables, is creating opportunities for innovations that offer extra value for users. These include furniture with built-in charging pads, cars that position the charging pad to keep mobiles safely out of reach while driving, and easy charging in hospitality locations such as cafes and restaurants. Chargers must be properly designed to protect consumers' products, particularly in high-power, fast-charging modes. The Qi logo is awarded after testing and certifying in accordance with the WPC-Qi specifications. STSAFE secure elements are loaded with official Qi Certificates and provide authentication that leverages state-of-the-art cryptography. The solutions clearly identify the charger and strictly attest to its authenticity as a Qi-certified product.

09:22 EDT Safe Bulkers refinances $70M of loan facilities - Safe Bulkers announced that the Company has entered into a credit facility of $70.0 million with a five-year tenor, comprising of a term loan tranche of $30.0 million and a reducing revolving credit facility tranche providing for a draw down capacity of up to $40.0 million, with respect to seven vessels. The agreement contains financial covenants in line with the existing loan and credit facilities of the Company. The proceeds from the credit facility will refinance loan facilities of $64.3 million, in respect of eight vessels maturing in 2023, seven of which will secure the new credit facility and one of which will remain debt free. The company does not intend to utilize the full capacity of the revolving credit facility tranche at this time. The refinancing transaction was evaluated and approved by the Board of Directors of the Company, excluding an independent member of the Board of the Company, who serves as the Chief Executive Officer of the financial institution that is the lender in the transaction. As of March 31, 2021, we had $607.6 million of outstanding debt. Following voluntary debt prepayments and debt payments in relation to vessels sales or debt refinancing in the aggregate amount of $106.9 million, scheduled principal payments of $4.5 million and loan drawdown of $30.5 million, we had as of June 18, 2021, outstanding debt of $526.7 million. On a pro-forma basis following this refinancing and assuming no draw down under the revolving credit facility, we will have outstanding debt of $500.2 million and availability of $67.5 million under our revolving credit facilities.

09:21 EDT German watchdog to examine Apple's 'digital ecosystem' - Germany's Federal Cartel Office said in a statement that it has initiated a proceeding against the technology company Apple (AAPL) based on the new competition law rules for large digital companies. This is the fourth large digital company against which the authority is taking action based on this new competition law tool. In the past months, the Bundeskartellamt has already initiated similar investigations against Facebook (FB), Amazon (AMZN) and Google (GOOGL). The Bundeskartellamt has initiated the first step against Apple in a proceeding to determine whether the company is of paramount significance across markets. An ecosystem which extends across various markets may be an indication that a company holds such a position. It is often very difficult for other companies to challenge such a position of power. Based on this first proceeding, the Bundeskartellamt intends to assess in more detail specific practices of Apple in a possible further proceeding. In this regard, the authority has received various complaints relating to potentially anti-competitive practices. These include, among others, an association complaint from the advertising and media industry against Apple restricting user tracking with the introduction of its iOS 14.5 operating system, and a complaint against the exclusive pre-installation of the company's own applications as a possible type of self-preferencing prohibited under Section 19a GWB. Andreas Mundt, President of the Bundeskartellamt: "We will now examine whether with its proprietary operating system iOS, Apple has created a digital ecosystem around its iPhone that extends across several markets. Apple produces tablets, computers and wearables and provides a host of device-related services. In addition to manufacturing various hardware products, the tech company also offers the App Store, iCloud, AppleCare, Apple Music, Apple Arcade, Apple TV+ as well as other services as part of its services business. Besides assessing the company's position in these areas, we will, among other aspects, examine its extensive integration across several market levels, the magnitude of its technological and financial resources and its access to data. A main focus of the investigations will be on the operation of the App Store as it enables Apple in many ways to influence the business activities of third parties." Reference Link

09:19 EDT Prometheus achieves $10M milestone payment from Dr. Falk Pharma - Prometheus Biosciences announced it has received a $10 million milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus' second program, PR600. Prometheus has selected a clinical candidate for PR600, targeting an undisclosed member of the tumor-necrosis factor superfamily for the treatment of IBD and is initiating IND-enabling studies. Under the collaboration agreement, which was executed in July 2020, Prometheus and Dr. Falk will share responsibility for the global development of PR600, with Dr. Falk contributing a certain portion of the external development costs associated with PR600 and its companion diagnostic. Dr. Falk acquired exclusive rights to commercialize PR600 in Europe, Australia and New Zealand, and Prometheus retains exclusive rights to commercialize PR600 in the United Stated and rest of world.

09:18 EDT Monro publishes corporate responsibility report - Monro released its inaugural Corporate Responsibility Report, Monro.Forward Responsibly, which covers fiscal year 2021. The report highlights the actions Monro is taking every day to care for its Teammates and customers, make a positive impact on the communities where it operates, and act as a good steward of the environment. Highlights and progress addressed in the report include: Strengthening the Board of Directors' ESG oversight through delegation of primary oversight to our re-named Nominating and Corporate Responsibility Committee. Enhancing Teammate engagement and prioritizing safety by conducting more robust and structured trainings and a commitment to offer Teammates clearly defined career paths, which have resulted in the lowest turnover rates in more than five years. Fostering diversity, equity and inclusion at all levels of the Company through our Teammate Resource Group and our training and recruiting initiatives. Making a positive impact in the communities where our Teammates work and live by volunteering and investing in more social programs that align with our mission and vision, which include providing access to basic needs for individuals and families. Reducing our energy footprint by including energy saving initiatives such as LED lighting and energy efficient signage in our store refreshment plan.

09:16 EDT Select Medical announces hospital, clinic acquisitions - Select Medical announced that it has entered into a series of transactions that will result in the company operating seven new critical illness recovery hospitals, licensed as long-term acute care, and eight new outpatient clinics through acquisitions and new joint venture partnerships. The transactions are subject to regulatory approval and expected to close by Q3/Q4 2021. Expanding its presence in Nashville, Select Medical has entered into a joint venture partnership with Ascension Saint Thomas to establish a new 30-bed critical illness recovery hospital inside Ascension's Saint Thomas Hospital West. It will be branded Select Specialty Hospital - Nashville West and be a satellite hospital to Select Specialty Hospital - Nashville, a 70-bed critical illness recovery hospital that has served the region since 1998. Select Medical signed a joint venture partnership to acquire an ownership interest and management services for eight HealthWorks Rehab & Fitness clinics in West Virginia. The deal also marks Select Medical's entrance into the state for outpatient physical therapy services. "Select Medical treats 82,000 patients a day across our post-acute care continuum. Since the outset of the COVID-19 pandemic, more than 16,000 patients requiring liberation from ventilators and extended specialty care as well as inpatient and outpatient rehabilitation have come through the doors of our hospitals, clinics and centers. The ability to extend that level of healthcare, quality and outcomes to new communities through these new joint venture partnerships is a privilege," said David Chernow, president and chief executive officer of Select Medical.

09:15 EDT Wrap Technologies announces expiration of warrants - Wrap Technologies announced that the exercise period of warrants issued in connection with the Company's 2019 offering of units consisting of common stock and warrants expired on Friday, June 18, 2021 and unexercised warrants are no longer exercisable. As part of its 2019 Unit Financing, the Company issued 1,923,076 warrants to participating investors, each exercisable at $6.50 per share, and 153,846 warrants to the placement agents for the 2019 Unit Financing, each exercisable at $8.125 per share. A total of 2,076,922 warrants, representing 99.9% of the warrants issued in connection with the 2019 Unit Financing, were exercised during the two-year term for proceeds to the Company of approximately $12.5 million. Approximatley $12.05 million of these proceeds were received this fiscal quarter to date ending on June 30, 2021.

09:13 EDT Midwest Energy Emissions to initiate testing on REE technology - Midwest Energy Emissions announced that the Company has retained the Pennsylvania State University's College of Earth and Mineral Sciences to evaluate the Company's Rare Earth Element Technology's capture capacity and regeneration potential under certain conditions. The evaluation period is set to begin in June and run through the end of September 2021.

09:11 EDT AYR Strategies opens third Pennsylvania dispensary in Gibsonia - Ayr Wellness announced the opening of the third Ayr medical dispensary in the Commonwealth of Pennsylvania, located in Gibsonia, a suburb of Pittsburgh. The Ayr Wellness dispensary is the third in the state opened by CannTech PA, LLC, a wholly-owned Ayr subsidiary. The strategic location, just off Route 8 at 112 Northtowne Square, Gibsonia, PA 15044, will see over 33,000 cars drive by per day. The 8,000 sq. ft. facility has 45 parking spaces and is designed to fit up to 30 point-of-sale stations. The dispensary will employ ~20 people from the local community and is located in the building that once housed King's Restaurant, an iconic family staple that has been closed since the beginning of the COVID-19 pandemic. Ayr Wellness will be the first dispensary located in Gibsonia and the surrounding area. It will feature curbside pickup and on-line reservations, a diverse product selection and will be open seven days a week.

09:11 EDT Mercer Park Brand Acquisition sets closing date for Glass House merger - Mercer Park Brand Acquisition Corp. is updating the status of its proposed merger with GH Group. The Company and GH Group have agreed that the closing conditions of the transaction have been met and have set a closing date of on or about June 29, 2021. An amended Merger Agreement containing minor modifications to facilitate closing arrangements will be filed with Canadian securities regulatory authorities shortly. As previously announced, with the business combination the Company and GH Group intend to create the largest cannabis brand-building platform in California, the world's largest cannabis market. GH Group will support its existing and future portfolio of brands with unmatched capacity and distribution in the state. The combined company has planned expansions to reach 6 million ft2 of cultivation in state-of-the-art greenhouses, representing by far the largest capacity of any cannabis operator in California and an anticipated retail footprint of 21 operational dispensaries by Q1 2022, more than double the next largest retail operator in the state.

09:09 EDT Auris Medical announces puvlication of results from study with OligoPhore - Auris Medical Holding announced the publication of results from an in vivo study demonstrating significant inhibition of tumor growth by siRNA knock-down of NF-B employing its OligoPhoreTM technology in Adult T-cell Leukemia Lymphoma. The article titled "Targeting NF-B with nanotherapy in a mouse model of adult T-cell leukemia / lymphoma" was published in Nanomaterials, an international peer-reviewed open-access journal. The study was performed jointly by research groups at Washington University, St. Louis MO, and the University of South Florida, Tampa FL. The researchers developed and evaluated RNA nanoparticles based on Auris Medical's OligoPhoreTM peptide carrier and siRNA targeting simultaneously two NF-B signaling pathways. NF-B is a protein complex that plays a key role in regulating the immune response to infection and is critical for tumor progression in ATLL. The siRNA nanoparticles were administered systemically to two groups of mice with either spontaneous ATLL tumor growth or tumor cell transplantation. The study demonstrated rapid delivery of siRNA to the tumor and significant reduction of target mRNA and protein expression, which altered the natural history of subsequent tumor progression. Tumor size, spleen size, and peripheral blood lymphocyte counts were significantly lower in treated mice compared to controls, and tumor growth was reduced to near zero in the most aggressive tumors. Further, the siRNA nanoparticles sensitized late-stage ATLL tumors to conventional chemotherapy with etoposide. ATLL is a rare and aggressive type of non-Hodgkin's lymphoma of mature T cells caused by the Human T-cell Leukemia / Lymphotropic Virus type 1. It can be found in the blood, lymph nodes, skin or other parts of the body. There are 5-10 million people infected with HTLV 1 globally, and it is estimated that 61 out of 100,000 of carriers will develop ATLL annually. The virus is endemic to Japan, sub Saharan Africa, South America, the Caribbean, central Australia, the Middle East, and Romania. Most cases are not curable with current treatments, even when diagnosed early. The 5-year survival rate is 23.4% with a median survival of 11 months. Overall survival has remained unchanged since the disease was first described.

09:07 EDT Department of Commerce imposes duties on silicon metal imports from Malaysia - Globe Specialty Metals and Mississippi Silicon, reported on June 17th that the U.S. Department of Commerce will impose final duties of 12.27% on all silicon metal imports from Malaysia. Today's decision closes out a set of investigations requested by GSM and MS last June to stop producers in four countries, including Malaysia, from selling dumped and unfairly subsidized metal imports into the United States - now, all have resulted in favorable final rulings. On March 24, 2021, the U.S. International Trade Commission unanimously determined that imports from Bosnia and Herzegovina, Iceland, and Kazakhstan are a cause of material injury to the U.S. industry. On April 19, 2021, Commerce issued final antidumping and countervailing duty orders imposing duties as high as 160% on all imports of silicon metal of Bosnia and Herzegovina, Iceland, and Kazakhstan. Following today's announcement, the ITC will provide an additional opportunity for comments before making its final determination. The schedule for these activities has not been released.

09:06 EDT Select Medical, Community Health partner to acquire Curahealth Tucson - Select Medical (SEM) and Northwest Healthcare, a subsidiary of Community Health Systems (CYH), announced the formation of a joint venture partnership and acquisition of Curahealth Tucson, a 47-bed long-term acute care hospital. The deal, subject to regulatory approval, is expected to close in early Q3 2021. "We are excited to partner with Northwest Healthcare to provide specialty care to high acuity patients in Tucson and surrounding communities," said Tom Mullin, executive vice president and chief operating officer of specialty hospitals at Select Medical. "This joint venture also further expands Select Medical's post-acute care footprint in Arizona, which now includes three Select Specialty critical illness recovery hospitals and three inpatient rehabilitation hospitals, with a fourth under construction." Under the joint venture, Select Medical and Northwest Healthcare plan to relocate the Curahealth Tucson hospital in September 2021 to the Northwest Transitions building, on the campus of Northwest Medical Center. Curahealth Tucson will be rebranded Select Specialty Hospital - Tucson Northwest and managed by majority owner Select Medical.

09:05 EDT Cassava Sciences to present SavaDx dataset at AAIC - SavaDx is an investigational diagnostic candidate to detect Alzheimer's disease with a simple blood test. SavaDx was evaluated for its ability to detect treatment effects of simufilam versus placebo in a randomized, controlled study completed in 2020. This was a Phase 2b study that enrolled 64 patients with Alzheimer's disease. The SavaDx clinical dataset will be presented at AAIC the week of July 26-30th.

09:04 EDT Cassava Sciences to initiate Phase 3 program of simufilam in 2H21 - Cassava Sciences plans to initiate a Phase 3 program of simufilam in Alzheimer's disease in the second half of 2021. A clinical research organization has been selected and will be publicly announced shortly. Large-scale, cGMP drug production capabilities are in-place to support the Phase 3 clinical program. Cassava Sciences' Phase 3 program consists of two double-blind, randomized, placebo-controlled studies in patients with mild-to-moderate Alzheimer's disease. The first Phase 3 study is designed to evaluate symptomatic improvement in Alzheimer's disease. The goal is to demonstrate improved cognition and daily function in subjects treated with simufilam compared to baseline and to placebo. Approximately 600 subjects will be enrolled, randomized to simufilam 100 mg or placebo BID, and treated for 12 months. Efficacy endpoints are ADAS-Cog, a cognitive scale, and ADCS-ADL, a scale of daily function. The second Phase 3 study is designed to evaluate disease-modifying effects of simufilam in Alzheimer's disease. The goal is to demonstrate a slower rate of decline in cognition and daily function in subjects treated with simufilam compared to placebo. Approximately 1,000 subjects will be enrolled, randomized to simufilam 100 mg, 50 mg or placebo BID, and treated for 18 months. Efficacy endpoints are ADAS-Cog and ADCS-ADL.

09:03 EDT Luby's signs agreement to sell Cafeteria Restaurant operations to Calvin Gin - Luby's announced the company has entered into an agreement to sell the Luby's Cafeteria restaurant business to a newly formed affiliate of Calvin Gin. The purchase by the Gin affiliate will include 32 of the existing locations of Luby's restaurants, all in Texas, and ownership of the Luby's Cafeteria brand. The acquisition of the Luby's cafeterias business does not include any of the real estate owned by Luby's, nor does it include any of the Company's Fuddruckers operations or the Company's Culinary Contract Service business. The structure of the transaction will allow Luby's to sell its real estate related to its cafeteria restaurant business to third parties and realize the related value for its shareholders. It is currently anticipated, following the closing of the transaction, that almost all employees at the 32 involved locations will be offered positions by the purchaser to remain at those store locations, employment that will likely total over 1,000 associates. It is currently anticipated that the Luby's Cafeteria operations sale transaction could provide Luby's with approximately $28.7M of value. There can be no assurance that the Company will realize or receive the full value of such consideration. The Company does not currently plan to adjust the estimated liquidation value of the Company as a result of this transaction. This amount does not include any value that may be obtained through future sales of Luby's owned real estate underlying 25 of the cafeteria locations.

09:02 EDT Lydall trading resumes

08:59 EDT AppHarvest starts construction on two new indoor firms - AppHarvest announced the start of construction for two new high-tech indoor farms in Central Appalachia. The company's new farms, located in Somerset and Morehead, Ky., will grow berries and leafy greens, respectively. The high-tech Somerset farm marks the company's expansion into growing berry crops. The Somerset indoor farm will be 30 acres. The high-tech Morehead, Ky. farm is the second AppHarvest farm in Rowan County to date. The new Morehead facility will produce leafy greens and will be about 15 acres. AppHarvest's newest indoor farms in Morehead and Somerset are preceded by the company's flagship 2.76-million-square-foot facility growing tomatoes in Morehead; a 15-acre facility in Berea that will grow leafy greens; and a 60-acre facility in Richmond that will grow vine crops. AppHarvest's goal is to operate 12 high-tech indoor farms by the end of 2025, and today's announcement means five of those now have been put on the map. Construction for both the Somerset and Morehead facility is anticipated to finish by the end of 2022.

08:56 EDT Hydrofarm announces redemption of investor warrants - Hydrofarm Holdings Group announced that the Company will redeem certain of its outstanding warrants Holders of the Investor Warrants have until 5:00 p.m. Eastern Time on July 19, 2021 to exercise their Investor Warrants. The Investor Warrants are exercisable for an aggregate of approximately 3.37 million shares of common stock, which reflects the total number of outstanding Investor Warrants as of June 15, 2021, at a price of $16.86 per share, representing approximately $54.0 million in total potential cash net proceeds to Hydrofarm. Following the redemption, and assuming all outstanding Investor Warrants are exercised, Hydrofarm expects to have approximately 43.2 million shares of common stock outstanding. Under the terms of the Investor Warrants, Hydrofarm is entitled to redeem all of the outstanding Investor Warrants for a redemption price of $0.00033712 per Investor Warrant if there is an effective registration statement covering the resale of the shares of common stock underlying the Investor Warrants, and the volume-weighted average price of the Company's common stock for the twenty consecutive trading days prior to the date of the notice of redemption is at least $25.28. These requirements have been achieved. Any Investor Warrants that remain unexercised immediately after 5:00 p.m. Eastern Time on July 19, 2021, the redemption date, will be void and no longer exercisable, and the holders of those Investor Warrants will be entitled to receive $0.00033712 per Investor Warrant.

08:53 EDT Q.E.P. Company declares one-time cash dividend of 5c per share - Q.E.P. CO. announced that on June 16, 2021, the Company's Board of Directors declared a one-time, cash dividend of $0.05 per share on the common stock of the Company. The cash dividend is distributable on or about August 18, 2021, to shareholders of record at the close of business on July 14, 2021.

08:52 EDT Ocean Power appoints Philipp Statmann as president, CEO - Ocean Power Technologies announced that its Board of Directors appointed Philipp Stratmann as its new President and CEO, and a Director. Mr. Stratmann previously served as OPT's Vice President of Global Business Development since 2019. In addition, the Board of Directors has elevated Matthew Shafer, to SVP, CFO and Treasurer. Stratmanne will be relocating from OPT's Houston office to the New Jersey headquarters. Mr. Shafer, already located in New Jersey, is a Certified Public Accountant, has an MBA in Finance from Rutgers Business School, and a bachelor's degree from The Stillman School of Business at Seton Hall University. Cryan also expressed thanks to George H. Kirby, who is departing OPT to pursue other endeavors, for his service as President and CEO since 2015.

08:48 EDT Hill International awarded contract by Aldar Properties - Hill International announced it has been awarded a contract by Aldar Projects LLC, the project delivery arm of UAE real estate developer Aldar Properties, to provide project management services for infrastructure upgrades in Abu Dhabi. The project consists of two distinct elements: The Zayed Link Road and Tal Moreeb Road. The Zayed Link Road project will refurbish and double the capacity of the existing link road between the E11 highway and the Madinat Zayed military airfield near the city of Madinat Zayed in the Al Dhafra Region. In total approximately 50 km of road will be converted from existing single carriageway to dual carriageway. The existing carriageway will also be refurbished. The Tal Moreeb Road project will construct a new dual carriageway from Liwa to the Tal Moreeb dune area to replace the existing road. The road length is approximately 22 km. Both elements are scheduled for completion in late 2022.

08:47 EDT Clearlake Capital-backed Unifrax to acquire Lydall for $62.10 per share - Unifrax announced it has signed definitive agreements to acquire Lydall. With its leading technologies and 23 manufacturing facilities around the world, Lydall is well positioned to capitalize on growth in clean air filtration and electric vehicle adoption, among many other attractive markets. Under the terms of the agreement, Lydall shareholders will receive $62.10 per share in cash for each share outstanding, implying a total enterprise value of approximately $1.3B. The transaction, which has been approved by the boards of directors of both companies, is expected to close in the second half of 2021 subject to the receipt of required regulatory approvals, approvals of Lydall stockholders and other customary closing conditions.

08:45 EDT Syneos Health accelerates decentralized clinical trial delivery - Syneos Health expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group, continuing the momentum for Decentralized Solutions demonstrated by the recent acquisition of Illingworth Research Group to move clinical trials closer to the patient. Decentralized Solutions from Syneos Health combines deep insights, agile technologies, innovative trial design experience and operational excellence - transforming product development. This novel, industry-leading Decentralized Clinical Trials Site Advocacy initiative takes decentralized methodologies and technologies to the next level, actively listening to find the right solutions. The Group will engage with sites and community stakeholders including patients, advocacy groups, industry, academic centers and sponsors, securing valuable insights across the clinical to commercial spectrum - from the mobile research nursing solutions provided by Illingworth Research Group to new and innovative mobile, digital and telemedicine capabilities - to better inform decentralized protocol design, data capture and patient retention strategies. The Group will pressure-test, problem-solve and co-create innovative decentralized clinical trial methodologies. The Group will also accelerate insights to enhance decentralized clinical trial implementation by driving an ongoing discussion about how to incorporate new technologies, making clinical trials more accessible to patients to facilitate better and more efficient solutions. This includes using mobile research, optimized digital health technologies and direct-to-patient logistics. Syneos Health deploys a Dynamic Assembly strategy, partnering with an open ecosystem of preferred best-of-breed data and technology collaborators to address decentralized study nuances.

08:45 EDT HP Enterprise acquires Determined AI - HP Enterprise announced that it has acquired Determined AI, a San Francisco-based startup that delivers a software stack to train AI models faster, at any scale, using its open source machine learning, or ML, platform. HPE will combine Determined AI's software solution with its AI and high performance computing, or HPC, offerings to enable ML engineers to implement and train machine learning models. Determined AI was founded in 2017 by Neil Conway, Evan Sparks, and Ameet Talwalkar, and based in San Francisco. It launched its open-source platform in 2020. Its solution has been adopted by customers across a wide range of industries, such as biopharmaceuticals, autonomous vehicles, defense contracting and manufacturing.

08:44 EDT Opko Health to develop, commercialize RAYALDEE in China with Nicoya - OPKO Health announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics, for the development and commercialization in Greater China of RAYALDEE for the treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease. Nicoya will make an upfront payment to OPKO of $5 million and an additional $5 million payment will be made during the first 12 months of the agreement or upon Nicoya achieving a certain predetermined development milestone. In addition, OPKO will be eligible to receive up to $115 million upon the achievement of certain development, regulatory and sales-based milestones. Nicoya will also pay OPKO tiered, double-digit royalties on product sales. Nicoya will be responsible for regulatory approvals and commercial activities pertaining to RAYALDEE in their territory.

08:42 EDT Curiosity Ink partners with Cepia to create video series for 'Cats vs Pickles' - Grom Social Enterprises, which recently entered into an agreement to acquire Curiosity Ink Media - a producer of original multiplatform family entertainment - announced that Curiosity has entered into a creative partnership with Cepia to "fortify 2021's biggest cat-tastic collectible craze, Cats vs. Pickles, into an original series, along with ancillary publishing extensions," the company said. "The partnership represents both companies' foray into the lucrative and highly profitable worlds of content distribution and publishing - offering new revenue streams for both - unlocking the potential for attendant ancillary businesses including international marketing, licensing and additional consumer products. The alliance will develop Cats vs. Pickles into a recurring series in 11-minute installments, as well as create revenue-generating extensions beginning with published content for consumer purchase," the company added. Cats vs. Pickles has no dialogue, and therefore no language or cultural barriers, and its potential for immediate global distribution makes it a unique and compelling programming asset. Simultaneously, Curiosity and Cepia will collaborate to produce a collection of picture, board and activity books expected to hit shelves in 2022.

08:40 EDT 23andMe appoints Valerie Montgomery to board of directors - 23andMe Holding announced that, following the June 16 closing of the previously announced business combination between 23andMe, Inc. and VG Acquisition, Dr. Valerie Montgomery Rice, the president and dean of Morehouse School of Medicine, became a member of its board of directors, joining Peter Taylor, president of the ECMC Foundation, along with Evan Lovell, Chief Investment Officer of the Virgin Group, and the five board members of 23andMe, Inc.

08:38 EDT Kymera Therapeutics presents preclinical data for KT-413 - Kymera Therapeutics announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents. The data were featured in an oral presentation at the 16th Annual International Conference on Malignant Lymphoma virtual meeting, taking place from June 18 - 22, 2021. IRAKIMiDs are novel heterobifunctional degraders designed to degrade both IRAK4 and IMiD substrates, including Ikaros and Aiolos, with a single small molecule. IRAKIMiDs synergistically target both the MYD88-NFkB and IRF4-Type 1 interferon pathways to enhance and broaden antitumor activity in MYD88-mutant diffuse large B-cell lymphoma. KT-413 is being developed initially for the treatment of relapsed/refractory MYD88-mutant DLBCL, with the potential to expand into other MYD88-mutant indications and IL-1R/NFkB-driven malignancies. KT-413 is currently in preclinical development and Kymera plans to submit an Investigational New Drug Application to the U.S. Food and Drug Administration in the second half of 2021 and, if cleared, initiate a Phase 1 clinical trial in patients thereafter. Data highlights include: In the OCI-Ly10 MYD88-mutant mouse xenograft model, intermittent dosing of KT-413 in vivo induced deep and sustained antitumor activity, including complete or partial regressions, that was superior to the clinically active IRAK4 kinase inhibitor CA-4948 or the latest generation IMiD CC-220. KT-413 showed strong tumor growth inhibition in multiple MYD88-mutant DLBCL patient-derived xenograft in vivo models. KT-413 showed strongly additive antitumor activity in combination with the anti-CD20 monoclonal antibody rituximab, the BTK inhibitor ibrutinib, or the BCL-2 inhibitor venetoclax, in MYD88-mutantOCI-Ly10 xenografts in vivo, suggesting the potential for therapeutically relevant drug combinations in MYD88-mutant DLBCL.

08:37 EDT SOS Limited enters joint venture agreement with Niagara Development - SOS announced that it has entered into a joint venture agreement with Niagara Development, a New Jersey limited liability company, for a joint venture to be based in Niagara, Wisconsin. The joint venture is expected to carry out crypto-currency mining operations and construct an international standardized Digital Super Computing Custody Operation Center. Under terms of the agreement, Niagara Development will be responsible for providing up to 150MW of electricity, including electricity generated from renewable sources, and construction the Digital Super Computing Custody Operation Center. SOS will be responsible for the management, operations and financing of the joint venture. SOS remains committed to its block-chain strategy and strive to become a sustainability leader in the industry. Yandai Wang, Chairman of SOS, commented, "SOS continues to increase its development of comprehensive blockchain solutions for digital trade, digital finance and other industries. We decided to acquire a sustainable power supply as far as possible, as we expand our blockchain operations into North America and look forward to successful operation of the joint venture. We continue to explore the possibility of acquisition of Niagara Development, Sherman Development LLC, and Park Falls Management LLC. Although at this point, we do not have any definitive agreement for such acquisition, we remain optimistic about our strategic expansion in North America."

08:36 EDT Lydall trading halted, news pending

08:36 EDT Qorvo announces shipment of family of dual-band GaN power amplifiers - Qorvo is now shipping a family of electronically reconfigurable dual-band GaN power amplifiers. The QPA0007 and QPA0004 are the first commercially available GaN PAs that can be rapidly reconfigured for operation between S- and X-bands. This enables a single radar platform to be used across multiple applications, offering precise long-range and short-range capabilities. This eliminates the need for independent systems, saving size, weight, power and cost. Now designers can dramatically reduce the BOM and footprint by as much as 50% while improving overall performance. The QPA0007 and QPA0004 are available in surface mount technology packaging and offer higher saturated power and power-added efficiency when compared to traditional switched dual-band solutions.

08:33 EDT CymaBay presents data from Phase 2 study, ENHANCE study of seladelpar - CymaBay Therapeutics announced data from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis. These data are being presented at The International Liver Congress 2021 of the European Association for the Study of Liver which will be held online June 23rd - 26th. In a poster presentation titled "Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis: a pooled analysis of phase 2 and phase 3 studies,"1 Stuart C. Gordon MD, Director of Hepatology for Henry Ford Health Systems, will be reporting the results of a pooled analysis of a subset of 39 patients with compensated cirrhosis from an open-label phase 2 study and a placebo controlled phase 3 study assessing the efficacy, safety, and tolerability of seladelpar at a daily dose of 5 mg or 10 mg in PBC patients who had an inadequate response or an intolerance to ursodiol. Cirrhosis was diagnosed using liver biopsy, imaging tests, or liver elastography. Efficacy analyses at 3 months included: Composite response defined as alkaline phosphatase less than 1.67 x upper-limit-normal, ALP decrease of greater than or equal to 15% and normal total bilirubin; Percent change from baseline in ALP; Normalization of ALP levels; Other measures of liver function. After 3 months, the composite endpoint was met in 50% of patients in the 5 mg and 63% in the 10 mg groups compared to none in Pbo. Levels of total bilirubin, platelets, albumin, and coagulation parameters remained stable. Seladelpar was well tolerated and appeared safe. Three patients with cirrhosis experienced an SAE, all unrelated to seladelpar. Efficacy, tolerability, and safety in patients with compensated cirrhosis were comparable to that of non-cirrhotic patients. A second clinical presentation will be delivered by Dr. Aliya Gulamhusein, Assistant Professor and Clinical Investigator at the Toronto Centre for Liver Disease, demonstrating that in 51 PBC patients previously treated with but no longer taking obeticholic acid or fibrates, seladelpar appeared to be safe, well tolerated and showed meaningful and dose dependent improvements in liver biochemistry, including in those taking 10 mg seladelpar a 45% reduction in ALP and a 79% composite response rate. In addition, there were no meaningful differences in the effects of seladelpar treatment between those with prior treatment with OCA or fibrates compared to those without prior treatment. Additionally, a presentation by Dr. Paul Watkins, Professor of Medicine at the University of North Carolina Chapel Hill, will highlight the ajudication of suspected drug-induced liver injury in non-alcoholic steatohepatitis patients using independent blinded review by a panel of pathologists and hepatologists. A comprehensive process of adjudication found no clinical, biochemical or histologic evidence that seladelpar was hepatotoxic. The process included two extensive rounds of blinded randomized review of all biopsies in the study. The panel concluded that there were no specific cases that were suggestive of DILI and the features identified by the study pathologists were present at baseline. The outcome of the pathology review indicates a need for further research into disease-related changes in the portal tracts of the livers of NASH patients. The panel also recommended that future biopsy trials in NASH should use blinded concurrent review of baseline and end of treatment biopsies. The report from the panel was subsequently submitted to the FDA and the FDA lifted the clinical hold on seladelpar across all three indications. Finally, a preclinical presentation4 will highlight that the combination of seladelpar and CB-0406 in a mouse model of NASH led to substantially greater reductions in fibrosis and NASH than either monotherapy.

08:33 EDT IAA acquires Auto Exchange operations - IAA announced that it has acquired the entirety of the assets of Marisat, doing business as Auto Exchange, a provider of personal service and security in the salvage recovery industry, effectively taking over the business operations of Auto Exchange. IAA will operate the business of Auto Exchange going forward. Financial terms of the transaction were not disclosed. Founded in 1979, Auto Exchange is a regional salvage industry leader in New Jersey. The acquisition will leverage existing assets to expand IAA's physical presence in New Jersey and allow IAA to further serve the growing needs of the market and clients in the area.

08:31 EDT ManTech wins $110M contract to develop naval radar, electronic warfare systems - ManTech announced a five-year, $110M contract to support Naval Surface Warfare Center Crane in developing and upgrading radar and electronic warfare systems for the U.S. Navy. ManTech was awarded this contract under the Department of Defense Information Analysis Center's multiple-award contract vehicle. These DoD IAC MAC task orders are awarded by the U.S. Air Force's 774th Enterprise Sourcing Squadron to develop and create new knowledge for the enhancement of the DTIC repository and the R&D and S&T community. ManTech will provide Intelligent Systems Engineering using the company's Model Based Systems Engineering Laboratory and Cognitive Cyber capabilities with its ACRE Cyber Range solution at the company's Crane, Indiana campus.

08:29 EDT Tian Ruixiang to step into healthcare management industry - TIAN RUIXIANG announced that the company plans to explore and expand into healthcare management industry. Zhe Wang, Chairman and CEO of the Company, commented, "We intend to utilize our experience in the insurance sector to expand into healthcare management industry. With the favorable government policies, such as the 'three-child' policy, and the trend of China's growing aging population, it is expected that the demand for healthcare management services will increase. We believe our plan to explore and expand into the healthcare management industry is in line with the social and macro environment development in China, and will create long-term value to our shareholders."

08:27 EDT Immutep to evaluate efti in triple combination therapy Phase I study - Immutep announces it has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy. INSIGHT-003 will be an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. The trial will be run as an amendment to the protocol of the ongoing INSIGHT trial as the third arm with Prof. Dr. Salah-Eddin Al-Batran as lead investigator. Up to 20 patients with various solid tumours will be recruited to participate in the trial. Patients will receive 30 mg doses of efti every two weeks for 24 weeks in conjunction with standard of care chemotherapy plus anti-PD-1 therapy. Thereafter, patients will enter a maintenance phase and receive either efti alone or in double or continued triple combination with anti-PD-1 therapy. The trial will assess the safety, tolerability and initial efficacy of the combination. All regulatory and ethical approvals have been received, enabling recruitment to commence. The first patient is expected to be enrolled in Q3 of calendar year 2021, with first interim results expected in 2022.

08:25 EDT BlackBerry QNX software embedded in over 195M vehicles - BlackBerry announced that Strategy Analytics, a leading independent research firm, has determined BlackBerry QNX software is now embedded in over 195M vehicles, an increase of 20M from the year before. "BlackBerry QNX is the market leader for safety-certified embedded software in automotive. Automakers and Tier 1s, including Aptiv, BMW, Bosch, Ford, GM, Honda, Mercedes-Benz, Toyota, and Volkswagen, trust BlackBerry QNX software for a broad range of critical systems," the company said. These include Advanced Driver Assistance Systems, Digital Cockpits and Secure Data Gateways. "BlackBerry continues to clearly demonstrate its leadership position in safety-critical embedded automotive software, with both an increased vehicle count and strong growth in royalty revenue backlog. Achieving over 195 million vehicles marks the sixth consecutive year that this count has increased," said John Chen, Executive Chairman & CEO, BlackBerry. "We continue to innovate our platform, which further strengthens our market advantage. BlackBerry QNX is very well positioned to capitalize on the secular trends of greater safety-critical software in the car, the transition to electric vehicles and the move towards autonomous drive."

08:24 EDT Gold Royalty Corp trading halted, news pending

08:23 EDT Magella, Enterprise team with ICE for new Houston crude oil futures - Magellan Midstream Partners (MMP), Enterprise Products Partners (EPD) and Intercontinental Exchange (ICE) today announced the establishment of a new futures contract for the physical delivery of crude oil in the Houston area. The Midland WTI American Gulf Coast contract is being launched in response to market interest for a Houston-based index with greater scale, flow assurance and price transparency. It will utilize the capabilities and global reach of ICE's industry-recognized, state-of-the-art trading platform and is due to be launched by ICE by early 2022, subject to regulatory approval. The quality specifications of the new futures contract will be consistent with a West Texas Intermediate crude oil originating from the Permian Basin with common delivery options at either the Magellan East Houston terminal or the Enterprise Crude Houston terminal. In support of this new futures contract, Magellan and Enterprise anticipate discontinuing their existing provisions for delivery services under the current futures contracts deliverable at each terminal once the new contract receives regulatory approval and is finalized.

08:22 EDT C4 Therapeutics presents preclinical data on CFT7455 - C4 Therapeutics presented pre-clinical data for CFT7455, the Company's lead program. CFT7455 is an orally bioavailable MonoDAC targeting IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin's lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. These results, which support clinical evaluation of CFT7455 in non-Hodgkin's lymphomas, were delivered as a poster presentation at the 16th Annual International Conference on Malignant Lymphoma. C4T conducted in vitro studies which demonstrated that CFT7455 binds to cereblon with high affinity, inducing potent and deep degradation of IKZF1 in pre-clinical NHL models. Notable observations include: Cellular competition studies confirmed the high potency of CFT7455 as a cereblon binder. Treatment of the KiJK cell line of anaplastic large cell lymphoma with CFT7455 for 6 hours led to an 89% reduction in IKZF1 protein levels. CFT7455 demonstrated potent antiproliferative activity across a panel of NHL cell lines with MYC, BCL2, and/or BCL6 translocations or rearrangements. This includes in vitro models of cutaneous T-cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, and high-grade B-cell lymphoma. In xenograft models of NHL, CFT7455 achieved improved in vivo potency and efficacy, including deeper and more durable tumor regressions in models of ALCL, diffuse large B-cell lymphoma and MCL, when compared to approved and investigational IMiD therapies. Notable observations include: CFT7455 treatment led to durable tumor regression associated with deep IKZF1 degradation and IRF4 downregulation in KiJK xenografts, where pomalidomide treatment was ineffective at a clinically relevant dose. In the TMD8 DLBCL xenograft model, which proved insensitive to IMiD treatment, CFT7455 promoted tumor regression. In the REC1 MCL xenograft model, doses of CFT7455 greater than or equal to 10 microgram/kg promoted tumor regression. Pharmacodynamic studies showed that CFT7455 promoted degradation of IKZF1 and downregulation of cyclin D1 and E2F1. CFT7455 achieved dose-dependent efficacy in both ALK- and ALK+ xenograft models, from 3-100 microgram/kg with regressions at doses greater than or equal to 30 microgram/kg. In addition, CFT7455 was shown to be between greater than30-100 times more potent than other IKZF1/3 degraders in development. Global proteomic studies showed only IKZF1/3 proteins were significantly degraded in DL-40 tumors with treatment of CFT7455, resulting in modulation of IFN-regulated genes. These results support continued development of CFT7455, which C4T is currently exploring for the treatment of relapsed or refractory multiple myeloma and non-Hodgkin's lymphomas following the initiation of a Phase 1/2 clinical study in June 2021.

08:20 EDT Aligos Therapeutics to present Phase 1 data for ALG-010133 - Aligos Therapeuticsannounced that a poster describing preliminary data in healthy volunteers from the ongoing Phase 1a/b multi-part umbrella clinical trial of Aligos' S-antigen Transport-inhibiting Oligonucleotide Polymers compound ALG-010133 will be presented at the European Association for the Study of the Liver Digital International Liver Congress 2021. ILC 2021 is being held virtually on June 23-26, 2021. The company will also present four other posters at the meeting, which are detailed below and highlight nonclinical data from multiple drug classes within Aligos' chronic hepatitis B portfolio: STOPS molecules, a novel capsid assembly modulator candidate, and the company's lead small interfering RNA and antisense oligonucleotide drug candidates. The posters are expected to be made available to conference registrants beginning June 23. Aligos' five ILC 2021 presentations, and their potential implications, are summarized below. ALG-010133: S-antigen Transport-inhibiting Oligonucleotide Polymer. Title: Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of ALG-010133, an S-antigen Transport-inhibiting Oligonucleotide Polymer for the Treatment of Chronic Hepatitis B. Summary: The poster details the initial safety and pharmacokinetics of single ascending doses (SAD) and multiple ascending doses of ALG-010133 in healthy volunteers. These SAD and MAD studies constitute two parts of a three-part, multicenter, double-blind, randomized, placebo-controlled study - ALG-010133-101. ALG-010133 was generally safe and well tolerated in HVs when given as single and multiple subcutaneous doses of up to 200 and 180 mg, respectively. No serious adverse events, adverse events leading to premature study drug discontinuation, nor concerning laboratory, ECG, vital sign or physical examination findings were reported. Injection site reactions were seen in 19% of ALG-010133-treated subjects. Based on the PK exposures achieved in HVs, we expect that weekly subcutaneous doses of 120 mg and higher will be evaluated in cohorts of CHB subjects in Part 3. These data formed the basis for the prior decision to initiate 12 weeks of ALG-010133 dosing in CHB subjects. To potentially mitigate any ISRs in CHB subjects, use of topical steroids has been implemented as a prophylactic measure. Title: Mechanism of Action of Hepatitis B Virus S-antigen Transport-inhibiting Oligonucleotide Polymers Molecule. Summary: In HepG2.2.15 cells transfected with the STOPS molecule ALG-10000, the molecule reduced both intracellular and extracellular S-antigen levels. As the molecule did not significantly co-localize with or bind to S-antigen, we believe it likely acts through other host cellular factors to reduce S-antigen levels. Five host proteins, all of which have roles in RNA processing, translation, or protein folding/degradation and are believed to function in viral replication and infection, were found to bind to ALG-10000: SRSF1, HNRNPA2B1, GRP78, RPLP1, and RPLP2. These data suggest that STOPS have a complex mechanism of action involving interactions with host factors which play a role in RNA processing, protein translation/folding, and transportation of the S-antigen protein. Title: Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity. Summary: As part of a strategy to develop multiple structurally diverse CAM candidates to inhibit HBV viral replication in CHB, the authors characterized ALG-000111, a novel Class II CAM candidate. In vitro, ALG-000111 demonstrated sub-nanomolar potency, sustained antiviral activity and significant HBV DNA knockdown. The compound's prodrug form, ALG-000286, showed strong in vivo antiviral activity in an AAV-HBV mouse model as measured by declines in HBV DNA. Further development of this candidate is warranted as part of a diverse CHB portfolio. Title: ALG-125755, A Small Interfering RNA Against Hepatitis B Virus Effectively Inhibits Hepatitis B Surface Antigen Secretion in HBV Cell Models and the AAV-HBV Mouse Model. Summary: Aligos' lead siRNA candidate, ALG-125755, which targets the small open reading frame of the S-antigen transcript in HBV, was shown to knock down S-antigen by 1.5 log10 IU/mL 28 days after a single subcutaneous dose of 5 mg/kg in the AAV-HBV mouse model of HBV infection. This encouraging degree of S-antigen reduction in vivo is corroborated by its potency in vitro, where the candidate demonstrated 23.9 pM and 28.8 pM EC50 values in two different cell culture assays. The compound also demonstrated a favorable pharmacological profile in vitro in multiple other cell culture systems. Taken together, these data suggest that the compound is a potent agent with respect to S-antigen reduction and warrants further development as a potential therapeutic for chronic hepatitis B. Title: Combination Drug Interactions of Hepatitis B Virus Small Interfering RNA and Antisense Oligonucleotides In Vitro and In Vivo. Summary: As ASOs and siRNAs utilize independent pathways to potentially reduce S-antigen levels, unconjugated forms of Aligos' siRNA candidate ALG-125755 and of Aligos' ASO candidate ALG-020572 were evaluated for any additive or synergistic effects with respect to S-antigen knockdown, both in vitro and in vivo. In vitro, in dual combinations with each other as well as with other anti-HBV agents such as nucleos(t)ide analogs and capsid assembly modulators, the siRNA or ASO candidate each demonstrated a range of additive to significantly synergistic effects, depending on the specific combination used. With one another, the siRNA and ASO candidates exhibited synergy in vitro. These in vitro effects were confirmed in an AAV-HBV mouse model of HBV infection, where the ASO and siRNA exhibited additive effects with respect to S-antigen knockdown when combined. Based on the results of these interaction studies, further study is warranted to identify the most strategic combinations of siRNA and ASO candidates in CHB.

08:15 EDT New data for Teva's fremanezumab injection for migraines presented at EAN - A new analysis presented by Teva Pharmaceutical Industries on AJOVY or fremanezumab, injection for the preventive treatment of migraine, indicates to the European neurology community that the medicine has a positive safety profile in relation to risk of cardiovascular events. The data, drawn from an analysis of three published Phase 3 studies of fremanezumab and presented at the 7th Congress of the European Academy of Neurology, EAN, showed minimal changes in the heart rate and blood pressure of those patients studied over a 12 week period. "As a CGRP inhibitor, fremanezumab has been shown to provide protection against migraine in suitable patients, and we remain focused on continued assessment of the safety profile of this therapy, particularly in relation to heart-related issues as it is believed CGRP itself acts as a 'safeguard' during cardiovascular ischemia and other events," said Dr Joshua M. Cohen, Senior Director and Global Therapeutic Area Lead, Migraine and Headache, Teva.

08:14 EDT Alignment Healthcare receives conditional approval to expand product lines - Alignment Healthcare announced a significant expansion of its plan portfolio with the addition of Dual-Eligible Special Needs Plans in 24 counties and Chronic Condition Special Needs Plans in 11 counties nationwide, pending regulatory approval. Individuals enrolled in both Medicare and Medicaid can select one of these D-SNP or C-SNP options during Medicare's annual enrollment period, which begins Oct. 15.

08:13 EDT Akero Therapeutics presents analyses from Phase 2a BALANCED study - Akero Therapeutics announced additional analyses from its Phase 2a BALANCED study of efruxifermin in NASH patients with F1-F3 fibrosis, which were presented in two posters at the 2021 International Liver Congress. These analyses show significant correlations between normalization of liver fat and improvements in markers of liver injury and fibrosis, as well as whole-body metabolism. The new analyses also show that combining ALT response of greater than or equal to 17 U/L with normalization of liver fat increases the power to predict resolution of NASH and NASH resolution combined with a 1-stage improvement in fibrosis. Abstract No. 1314: "The role of reduction in liver fat content and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial," presented by Rohit Loomba, M.D. Abstract No. 1762: "Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, metabolism, and in histologic parameters following treatment with efruxifermin," presented by Stephen Harrison, M.D. EFX is currently being evaluated in a Phase 2b clinical trial in patients with F2/F3 fibrosis, the HARMONY study. A second Phase 2b clinical trial in patients with Cirrhotic NASH is planned for the second half of 2021.

08:10 EDT 51Job trading halted, news pending

08:09 EDT MicroStrategy purchases additional 13,005 bitcoins for $489M in cash - MicroStrategy (MSTR) announced that it had purchased an additional approximately 13,005 bitcoins (BTC) for approximately $489M in cash at an average price of approximately $37,617 per bitcoin, inclusive of fees and expenses. As of June 21, MicroStrategy holds an aggregate of approximately 105,085 bitcoins, which were acquired at an aggregate purchase price of approximately $2.74B and an average purchase price of approximately $26,080 per bitcoin, inclusive of fees and expenses.

08:07 EDT NV5 Global awarded $6M transportation infrastructure contract by Fresno - NV5 Global announced that the City of Fresno, California has selected NV5 for a $6.3 million contract to provide program management services for the Veterans Boulevard Interchange and Corridor Improvement Project, a major arterial road and interchange in California's Central Valley. The project includes the expansion of Veterans Boulevard to a six-lane roadway, a new interchange with State Route 99 including four bridges, and improvements to the surrounding roadways. Under this contract, NV5 will provide owner's representative services, project management, inspection services, and additional support services. The project is expected to be completed in December 2024.

08:07 EDT Orbital Energy's Gibson Technical awarded distributed antennae system project - Orbital Energy announced that its telecommunications subsidiary, Gibson Technical Services, has been awarded a project by a major U.S. cellular carrier to install a distributed antennae system in a large Atlantic Athletic Conference university stadium. The project is scheduled to commence in the coming weeks and to be completed during the 2021 ACC football season. Mike McCracken, GTS's CEO, commented, "Being awarded this project from a leading telecommunications services provider for a major university stadium recognizes GTS's ability to deliver high quality engineering and construction services. It also reflects how DAS projects are now coming back online, after being largely delayed due to the pandemic."

08:05 EDT Bally's announces multi-year market arrangement with Boot Hill Casino & Resort - Bally's announced that it has entered into a multi-year market arrangement with Boot Hill Casino & Resort, located in Dodge City, Kansas. "With the pending Kansas state sports betting legislation, Boot Hill Casino is committed, as a manager on behalf of the Kansas Lottery, to timely and effectively implement "Bally Bet," Bally's mobile sportsbook, to provide Kansas sports fans access to sports betting upon enactment of the legislation. Bally's expects that its media partnership with Sinclair Broadcast Group, which provides it with access to integrate content into Sinclair's portfolio of 19 regional sports networks, will also attract sports fans in neighboring states to the Kansas mobile sportsbook," the company said. All gaming in Kansas is owned and operated by the Kansas Lottery. The arrangement, as required by law, would license, transfer or lease the necessary Bally's mobile sportsbook elements to the Lottery to offer Kansas sports fans a premium sports betting platform.

08:04 EDT Farmers National Banc CFO Carl Culp announces retirement - Farmers National Banc announced the following changes in its Accounting and Finance Executive Group. The changes are prompted by Carl D. Culp's decision to retire as Farmers National Bank Chief Financial Officer and Senior Executive Vice President, effective August 15, 2021. The decision ends Culp's highly successful 36-year career in accounting and the financial services industry, with 32 years dedicated to Farmers National Bank, including the last 25 years as Farmers' Chief Financial Officer and Senior Executive Vice President. Culp has agreed to provide advisory services for a period of time to ensure a seamless transition to his successor.

08:03 EDT Huntington Ingalls announces international order for REMUS 300 UUVs - Huntington Ingalls Industries announced that the Royal New Zealand Navy has placed the first international order for four REMUS 300 unmanned underwater vehicles. New Zealand has a fleet of six REMUS 100 UUVs that are used for mine countermeasures and underwater survey operations. The Royal New Zealand Navy has also used its REMUS vehicles for search and recovery, including locating the wreck of the Princess Ashika ferry in 2009 and assisting with the White Island volcano search effort in 2019.

07:49 EDT One Liberty Properties trading resumes

07:41 EDT Rada Electronic partners with BeyondMinds on AI solutions for tactical radars - RADA Electronic Industries and BeyondMinds have executed a Letter of Intent to establish strategic teaming to develop and productize advanced AI and deep learning solutions for RADA's tactical radars. RADA has defined AI as a core capability, and has recently assembled a core group, which along with BeyondMinds' cutting-edge AI models and unique solutions, is expected to maintain and enhance RADA's leadership in the market of tactical radars for the maneuver force. Solutions will focus on increased accuracy, advanced target classification and dynamic adaptation of radar performance to the ever-changing operational environment. A definitive agreement is due by end of July 2021.

07:39 EDT LA Metro selects Parsons for I-10 express lane project - Parsons Corporation announced that the company has been selected by the Los Angeles County Metropolitan Transportation Authority to provide full engineering services in preparing environmental reporting and concept of operations for 17 miles of express lanes on Interstate 10. The $23.5M contract builds on Parsons' relationship with LA Metro while helping improve transportation in the Los Angeles region. The 17-mile express lane segment project will connect two existing segments, completing a continuous 64-mile express lane corridor along I-10 from Alameda Street to Ford Street. As part of the contract, Parsons will also assist LA Metro in determining the appropriate delivery method for the next phase of the project.

07:37 EDT One Liberty Properties sells retail property for $40.5M - One Liberty Properties (OLP_ announced that it closed on a $40.5M sale of a 47,200 square foot building and the related parking lot located in West Hartford, Connecticut and leased to Whole Foods. The proceeds were used to repay a $15.4M mortgage on the property, pay off the $17.9M outstanding balance on the Company's credit facility and pay transaction related costs. The remaining proceeds of approximately $5.4M will be used for general corporate and working capital purposes. The Company anticipates that for the quarter ending June 30, 2021, it will recognize an approximate net gain of $21.5M from this sale, before giving effect to a $796,000 mortgage swap termination fee. During the three months ended March 31, 2021, the Company recognized $440,000 of rental income and incurred $132,000 of mortgage interest expense and $80,000 of depreciation and amortization expense at this property. The Company and Havertys (HVT), entered into new leases which extended the lease term on ten of the eleven properties that had been scheduled to expire in August 2022, although one of these leases provides that it can be terminated by either party prior to the stated termination date. Generally, the lease extensions run for four to nine years from the August 2022 expiration date. The Company also agreed to invest up to $3M for tenant improvements. After giving effect to the lease extensions and assuming the lease subject to the mutual termination right is not terminated, rental income from this tenant is anticipated to be approximately $4.8M, $4.5M and $4M in 2021, 2022 and 2023, respectively.

07:35 EDT Arrowhead, Horizon Therapeutics enter ARO-XDH license agreement - Arrowhead (ARWR) and Horizon Therapeutics (HZNP) announced a global collaboration and license agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference, or RNAi, therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. Under the terms of the agreement, Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic. Horizon will receive a worldwide exclusive license to the therapeutic and will be wholly responsible for clinical development and commercialization. Arrowhead will receive $40M as an upfront payment from Horizon and is eligible to receive up to $660M in potential development, regulatory and commercial milestones, and is further eligible to receive royalties in the low- to mid-teens range on net product sales.

07:33 EDT Ollie's announces change to participation date at Jefferies conference - Ollie's Bargain Outlet Holdings announced that the Company will now be participating in a fireside chat at the 2021 Jefferies Virtual Consumer Conference on Wednesday, June 23, 2021, at 2:40 PM ET. Attending for Ollie's will be John Swygert, President and CEO and Jay Stasz, SVP and CFO.

07:29 EDT GasLog Partners enters charter agreement with Cheniere Energy - GasLog Partners LP ("GLOP) announced a new time charter agreement for the Methane Heather Sally with a wholly owned subsidiary of Cheniere Energy, Inc. (LNG). The charter began last week and has a minimum duration one year. Cheniere have the option, until late August, to extend the charter for an additional one or two years. The Methane Heather Sally is a 145,000 cbm steam turbine LNG carrier built in 2007 which previously operated in the spot market.

07:22 EDT L Brands files Form 10 registration statement for planned VS separation - L Brands, Inc. announced the public filing of a Form 10 registration statement with the U.S. Securities and Exchange Commission in connection with the previously announced separation of the Victoria's Secret business into an independent, public company. The new company, named Victoria's Secret & Co., will include Victoria's Secret Lingerie, PINK and Victoria's Secret Beauty. The filing provides detailed information on Victoria's Secret's business, strategy and historical financial results. As previously announced, the separation is currently expected to be completed in August 2021, subject to certain customary conditions, including final approval by the L Brands Board of Directors and effectiveness of the Form 10 registration statement.

07:20 EDT GameStop appoints Matt Furlong to board of directors - GameStop announced the appointment of Matt Furlong to the Company's Board of Directors, effective immediately. The appointment date aligns with Mr. Furlong's start date as GameStop's new CEO. Coinciding with Mr. Furlong's appointment, George Sherman has retired from the Board. Five of the six members of the Board remain independent.

07:19 EDT Vislink adjourns Annual Meeting to July 19 - Vislink announced that its 2021 annual meeting of stockholders, which was originally scheduled for June 21, 2021, will be convened and adjourned, without any business being conducted, due to lack of the required quorum. The Annual Meeting will be adjourned to 9:00 a.m. on July 19, 2021 to allow additional time for the Company's stockholders to vote on the proposals set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission.

07:17 EDT Wood Mackenzie welcomes Quinbrook Infrastructure as development partner - Wood Mackenzie welcomes Quinbrook Infrastructure Partners as a development partner for the Lens decision intelligence platform. With its analytics-ready power and renewables data integrated into a single platform, Lens Power enables organisations to maximise investment opportunities in clean energy and be on the forefront of the energy transition.

07:15 EDT Anavex announces data from Phase 2 trial of ANAVEX 2-73 - Anavex Life Sciences Corp. reported predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary clinical efficacy endpoints from the U.S. Phase 2 randomized, double-blind, placebo-controlled trial of ANAVEX 2-73 in adult female patients with Rett syndrome. ANAVEX 2-73 activates the sigma-1 receptor. Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity. Recent independent findings strengthen the understanding of the beneficial effect of SIGMAR1 activation as compensatory mechanism to chronic CNS diseases. Rett syndrome is a chronic CNS disease caused by a spontaneous mutation of one gene, MECP2. This study demonstrates for the first-time that a biomarker correlates with clinical efficacy in Rett syndrome. ANAVEX 2-73 treatment resulted in increases in the mRNA expression of SIGMAR1, the gene coding for the receptor targeted by ANAVEX 2-73, which correlated with clinical efficacy as measured by both primary efficacy endpoints, namely RSBQ and CGI-I. In addition, prespecified patients with WT SIGMAR1 in the clinical trial demonstrated a clinically meaningful and statistically significant 14.5-point improvement over placebo in the RSBQ total score, the trial's key efficacy endpoint. This magnitude of the improvement with ANAVEX 2-73 compares favorably to published data currently in clinical development, which reported an average difference of 4.4 points in RSBQ total score versus placebo, despite an advantage of higher dose and lower age compared to ANAVEX 2-73-RS-001 trial. The RSBQ demonstrated balanced improvements across all the instrument's subscales during the trial period of 7 weeks, including general mood, breathing, hand behavior, repetitive face movements, body rocking, night-time behavior, fear/anxiety, walking/standing. The Anxiety, Depression, and Mood Scale, which is a measure of anxiety and mood symptoms in individuals with intellectual disability, has been clinically validated for use in Rett syndrome and in Fragile X syndrome, demonstrated clinically meaningful and statistically significant 12.9-point improvement for ANAVEX 2-73 treated adult patients with Rett syndrome vs placebo in prespecified patients with WT SIGMAR1. The ADAMS also demonstrated balanced improvements across all different subscales during the trial period of 7 weeks, including manic/hyperactive behavior, depressed mood, social avoidance, general anxiety, obsessive compulsive behavior. Anavex is planning to meet with the FDA to discuss the approval pathway. There are no FDA-approved drugs for Rett syndrome. ANAVEX 2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome and may be considered for accelerated approval.

07:11 EDT GSK, Vir Biotechnology report results from Phase 3 study of sotrovimab - GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) today announced final, confirmatory results from the Phase 3 COMET-ICE trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalization or death among high-risk adult outpatients with mild-to-moderate COVID-19. Additionally, the U.S. National Institutes of Health updated its COVID-19 treatment guidelines to recommend sotrovimab for non-hospitalized patients with mild-to-moderate COVID-19 who are at high risk of clinical progression and noted that sotrovimab appears to retain activity against current variants of concern and interest. The primary efficacy analysis of all 1,057 patients in the COMET-ICE trial demonstrated a 79% reduction in hospitalization for more than 24 hours or death due to any cause, by Day 29 compared to placebo, meeting the primary endpoint of the trial. The number of patients in the trial who were hospitalized for greater than24 hours for acute management of any illness or death from any cause at Day 29 was six patients in the sotrovimab arm, versus 30 patients in the placebo arm. In the sotrovimab arm, it is possible that half of those patients who were hospitalized were for reasons other than progression of COVID-19; this was not the case for patients in the placebo arm. In the safety analysis, 1,037 participants were followed through at least 29 days. The most common adverse events observed in the sotrovimab treatment group in COMET-ICE were rash and diarrhea, all of which were Grade 1 or Grade 2. No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo. The companies plan to submit the full COMET-ICE data set to a peer-reviewed journal for publication. The NIH recently updated its guidelines regarding the emergency use authorizations of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 in the U.S. to recommend the use of sotrovimab for non-hospitalized patients with mild-to-moderate COVID-19 who are at high risk of clinical progression. The guidelines note that the target binding site of sotrovimab is in a region of the virus that does not overlap with the binding site location of key mutations in current variants of concern and interest. These guidelines were based upon an interim analysis of 583 patients in the COMET-ICE trial, which was stopped early in March 2020 by an independent data monitoring committee because interim results demonstrated evidence of sotrovimab's clinical efficacy. The interim study results demonstrated an 85% reduction in hospitalization for more than 24 hours or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial. These data have informed global regulatory reviews to date, including the positive scientific opinion issued by the European Medicines Agency's Committee for Human Medicinal Products under Article 5(3) of Regulation 726/2004, as well as the Emergency Use Authorization granted by the U.S. Food and Drug Administration. The companies are actively working with government agencies around the world to make sotrovimab available to patients in need of treatment. GSK and Vir plan to submit a Biologics License Application to the U.S. FDA in the second half of 2021. The EMA has started a rolling review of data on sotrovimab that will continue until enough evidence is available to support the filing of a formal marketing authorization application. The companies' strategic manufacturing network is enabling the manufacture of approximately two million doses to support emergency supply in the first year following U.S. Emergency Use Authorization, with approximately 450,000 doses on hand.

07:09 EDT Taysha Gene publishes new analysis of of natural history data for TSHA-120 - Taysha Gene Therapies announced the publication of new analyses of natural history data for TSHA-120 in giant axonal neuropathy, or GAN. The data were published online and will be included in the June edition of Brain, a highly esteemed neurological science peer-reviewed journal. GAN is a progressive neurodegenerative disease that affects both the central and peripheral nervous systems. The disease is caused by loss-of-function mutations in the gene coding for gigaxonin, which results in dysregulation of intermediate filament turnover, an important structural component of the cell. Although no symptoms are present in the first few months of life, many children with GAN do show early symptoms and features before the age of five, including unsteady gait, frequent falls, and motor weakness. Symptoms worsen over time and children develop scoliosis, contractures, atrophy of the spinal cord and abnormalities of the white matter in the brain. Currently, there are no approved treatments for GAN, which results in death for patients in their late teens or early twenties.

07:07 EDT RedHill Biopharma announces presentation of oral opaganib phase 2 data - RedHill Biopharma announced presentation of the "positive" Phase 2 safety and efficacy data for oral opaganib in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum 2021. Results and post hoc analyses of data from the 40-patient U.S. Phase 2 study were presented in a poster entitled, "Opaganib, an Oral Sphingosine Kinase-2 Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia." Patients in the study were randomized to receive either opaganib or placebo in addition to standard of care, predominantly including dexamethasone and/or remdesivir. Findings include: 50% of patients treated with opaganib reached room air by Day 14 compared to 22% in the placebo group. The benefit of reaching room air by Day 14 for patients on opaganib was maintained regardless of whether the patients were receiving dexamethasone and/or remdesivir. 86.4% of patients treated with opaganib were discharged from hospital by Day 14 compared to 55.6% of patients treated with placebo. Median time to discharge was 6 days for the opaganib group compared to 7.5 days for the placebo group. 81.8% of opaganib patients achieved a 2-point improvement in the WHO Ordinal Scale compared to 55.6% of patients in the placebo group - achieved in a median time of 6 days versus 7.5 days, respectively. No significant differences in safety-related measures between the two groups. The global 475-patient Phase 2/3 study of opaganib in severe COVID-19 has been approved in 10 countries and completed enrollment, through 57 participating sites, on June 6th. The primary endpoint of the study is the proportion of patients breathing room air without oxygen support by Day 14. Additional important outcome measures, such as time to discharge from hospital, improvement according to the World Health Organization Ordinal Scale for Clinical Improvement and incidence of intubation and mortality, will also be captured in the follow-up period of up to 6 weeks. The study received four independent DSMB recommendations to continue following unblinded safety reviews and a futility review. Additionally, an evaluation of the blinded blended intubation and mortality rates to date was encouraging as compared to reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations.

07:05 EDT Torchlight Energy Resources, Metamaterial extend closing date for combination - Torchlight Energy Resources announced that Torchlight and Metamaterial have agreed to extend the outside date by which Torchlight and Metamaterial must close their business combination transaction to June 30. The extension provides time for the June 24 record date and the June 25 payment date of the special Series A Preferred Stock dividend, declared on June 14, to transpire. The payment date for the Series A Preferred Stock dividend will be June 25. The Company expects to close the arrangement no later than June 30th.

07:05 EDT ZIM Integrated, Alibaba.com announce extension of agreement until 2023 - ZIM Integrated Shipping Services (ZIM) and Alibaba.com (BABA) announced that they will extend their cooperation agreement for two more years. The agreement which enabled Alibaba.com sellers to book and purchase sea freight on ZIM and logistic services from ZIM Logistics China, a wholly-owned subsidiary of ZIM, has now been expanded to include serving Alibaba.com buyers as well. "This collaboration helps Alibaba.com offer its customers a more affordable transit alternative relative to air freight with an easy-to-use interface available directly on the Alibaba.com platform. ZIM's extensive network of lines, particularly the recently introduced dedicated eCommerce express lines, provide Alibaba.com customers reliable, fast, high quality freight services, as well as product support and system optimization," the company said. The successful cooperation has been in place since 2020 and the significant growth of eCommerce and demand for freight capacity in the last year have led the parties to deepen their collaboration.

07:03 EDT Ingersoll-Rand to acquire Seepex for EUR 431.5M in all-cash transaction - Ingersoll Rand has entered into an agreement to acquire positive displacement pump manufacturer, Seepex. The all-cash transaction, valued at EUR 431.5M, is expected to close during Q3 upon obtaining required regulatory approvals. Seepex is a manufacturer of progressive cavity pumps, a segment of positive displacement pumps that primarily serves water, wastewater, food and beverage, and chemical end markets. Based in Bottrop, Germany with facilities in North America and Asia Pacific, Seepex has approximately 800 employees and annual revenue of approximately EUR 160M. Upon transaction close, the Seepex business will join the Ingersoll Rand Precision and Science Technologies segment.

07:03 EDT Agios Pharmaceuticals submits NDA for mitapivat for PK deficiency - Agios Pharmaceuticals announced that it has submitted a New Drug Application for mitapivat to the U.S. Food and Drug Administration for the treatment of adults with pyruvate kinase deficiency. The NDA submission is based on results from two pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively. A full analysis of these data - including patient-reported outcomes - was recently presented at the European Hematology Association Virtual Congress. An extension study for adults with PK deficiency previously enrolled in ACTIVATE or ACTIVATE-T is ongoing and designed to evaluate the long-term safety, tolerability and efficacy of treatment with mitapivat. The company remains on track to submit a marketing authorization application in the EU in mid-2021 for mitapivat in adults with PK deficiency.

07:02 EDT Day One receives orphan designation from European Commission for DAY101 - Day One Biopharmaceuticals announced that the European Commission has granted orphan designation for the Company's lead product candidate, DAY101, for the treatment of glioma. The designation was based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products. DAY101 is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway. Day One is conducting a pivotal Phase 2 clinical trial of DAY101 in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma harboring a known BRAF alteration.

06:49 EDT Summit Midstream ups FY21 adjusted EBITDA view to $225M-$240M from $210M-$230M - Management now expects total indebtedness as of June 30, net of unrestricted cash on hand, to be reduced by approximately $82M, which is nearly 6% lower than the outstanding net debt balance as of December 31, 2020. Heath Deneke, president, CEO and chairman, commented, "Summit's year to date financial and operational results continue to exceed our original expectations, largely driven by the outperformance from wells turned in line year to date, accelerated customer activity, and continued gains from expense management initiatives that have been implemented across the organization. While we still expect 2021 to be a trough year for new well connect activity across our footprint, we are encouraged by the strengthening commodity price backdrop and increasing customer activity now expected during the second half of the year. As a result of year to date outperformance and accelerated well activity, we are increasing our full year 2021 adjusted EBITDA guidance to a new range of $225 million to $240 million. We are maintaining our 2021 capital expenditure guidance range of $20 million to $35 million."

06:38 EDT Tanzanian Gold announces discovery at Buckreef Gold project - Tanzanian Gold Corporation and its joint venture partner, The State Mining Company announce that it has made a new discovery of three closely spaced parallel, gold bearing structures at the Buckreef Gold Company Limited's project, collectively now known as the Anfield Zone. Highlights: The new prospective gold mineralized zones, totaling a combined 2.9 kilometer strike length were identified through geological mapping, sampling and examination of artisanal workings. Collectively, they have been named the Anfield Zone. Grab samples of mineralized bed rock have been assayed, with highlights of: 37.52 g/t, 28.55 g/t and 14.42 g/t. Located approximately 500 meters to the east of the Buckreef Gold Main Zone. Aligns with and trends towards the Eastern Porphyry Mineral Resource. Follow-up field work and diamond drilling planned for 2021 and 2022. Stephen Mullowney, CEO commented, "As part of the new management team's continued in-depth assessment of the Buckreef Gold asset and empowerment of local management, we continue to be excited by the greenfield exploration potential of the Buckreef Gold land package. Along with the announced Buckreef West discovery, the Anfield Zone is our second new discovery in less than 2 months. Combined with the positive metallurgical results, in conjunction with the Buckreef Gold Main Zone, these discoveries provide us with continued confidence that Buckreef Gold will develop into a significant gold producing asset."

06:33 EDT MediciNova announces publication of results from Phase 2 trial of MN-166 - MediciNova announced that results from a Phase 2 trial of MN-166 in alcohol use disorder were published in Nature's Translational Psychiatry. The clinical trial was a collaborative effort between MediciNova and Dr. Lara Ray, Professor, Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute at the University of California at Los Angeles and was funded by the Center for Study of Opioid Receptors and Drugs of Abuse. This study was a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 AUD patients were enrolled in this trial. The publication, entitled "Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial" was authored by Dr. Lara Ray and colleagues at UCLA. Key results reported in the publication include the following: Ibudilast did not have a significant effect on negative mood. Ibudilast, relative to placebo, reduced the odds of heavy drinking across time by 45%. Ibudilast attenuated alcohol cue-elicited activation in the ventral striatum compared to placebo. Alcohol cue-elicited activation in the VS predicted subsequent drinking in the ibudilast group, such that individuals who had attenuated ventral striatal activation and took ibudilast had the fewest number of drinks per drinking day in the week following the scan. Ibudilast reduced alcohol craving compared to placebo on non-drinking days. These findings extend preclinical and human laboratory studies of the utility of ibudilast to treat AUD and suggest a biobehavioral mechanism through which ibudilast acts, namely, by reducing the rewarding response to alcohol cues in the brain leading to a reduction in heavy drinking.

06:15 EDT Crypto names fall as bitcoin slips below $33,000 - In early pre-market trading, shares of Riot Blockchain (RIOT) are down 7.2% at $29.87 and Marathon Digital (MARA) are down 7.3% at $26.81 as the price of bitcoin fell over 7% to a two-week low below $32,200. Shares of Coinbase (COIN) are also down 2.8% at $222.88.

06:12 EDT Theravance Biopharma announces nezulcitinib trial did not meet primary endpoint - Theravance Biopharma announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo, each in combination with standard of care. Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase, or JAK, inhibitor in development for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation. The study was a 1:1 randomized, double-blind, placebo-controlled, multi-center Phase 2 trial for the treatment of hospitalized COVID-19 patients with impaired oxygenation. Key endpoints were measured through Day 28. Standard of care in the study included approximately 99% receiving steroids. There was no statistically significant difference in RFDs from randomization through Day 28 between nezulcitinib and placebo in ITT. Also, there was no difference in change from baseline at Day 7 in SaO2/FiO2 ratio, proportion of patients in each category of the 8-point Clinical Status scale, and proportion of patients alive and respiratory failure-free at Day 28. Nezulcitinib demonstrated a favorable trend in improvement when compared to placebo for 28-day all-cause mortality and time to recovery. In patients with CRP less than150 mg/L, there was an improvement in those treated with nezulcitinib when compared to placebo in: 28-day all-cause mortality and time to recovery. In patients with CRP greater than 150 mg/L, there was no difference in time to recovery or 28-day all-cause mortality between those treated with nezulcitinib or placebo. Nezulcitinib was well-tolerated; adverse events and serious adverse events occurred in 34.0% and 9.7% of patients treated with nezulcitinib, and 41.2% and 15.7% of patients treated with placebo, respectively. Adverse events of liver abnormalities or disease occurred in 9.7% and 7.8% of patients treated with nezulcitinib and placebo, respectively. Serious infections and venous thromboembolism occurred in 1% and none of the patients treated with nezulcitinib, and 2% and 4.9% in patients treated with placebo, respectively. Plasma exposure of nezulcitinib was low and consistent with expectations for a lung-selective medicine. The company will share these results with FDA and other regulatory agencies to seek input on protocols to further study nezulcitinib in acute hyperinflammation in the lung.

06:09 EDT Tarsus Pharmaceuticals says Saturn-1 trial met all primary, secondary endpoints - Tarsus Pharmaceuticals announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase 2b/3 Saturn-1 trial evaluating the company's novel investigational therapeutic, TP-03, in patients with Demodex blepharitis. Results demonstrated a statistically significant complete collarette cure at day 43 in patients with Demodex blepharitis treated with TP-03 compared to vehicle. The Saturn-1 trial also met the secondary endpoints of mite eradication at day 43 and composite cure based on complete collarette and erythema cures at day 43. In addition, significant, clinically meaningful improvements were observed within two weeks across multiple endpoints. TP-03 was well tolerated with a safety profile similar to vehicle, and there were no treatment-related discontinuations. Results demonstrated 81% of patients achieved a significant, clinically meaningful collarette cure defined by a collarette grade of zero or one at day 43 compared to 23% of those on vehicle. Additionally, a significant, clinically meaningful collarette cure was seen in 23% of patients on TP-03 compared to 11% on vehicle as early as day 8. Saturn-1 data also showed that 43% of patients on TP-03 achieved the primary endpoint of complete collarette cure at day 43, defined as zero to two collarettes per lid compared to 7% on vehicle. Collarettes, a pathognomonic sign of Demodex infestation, are composed of partially digested epithelial cells, mite waste products and eggs and are most easily observed at the base of the upper eyelashes when the patient looks down during a standard eye examination. The secondary endpoint of complete mite eradication achieved statistically significant results by day 15, and 68% of patients on TP-03 achieved mite eradication compared to 18% on vehicle at day 43. Mite eradication is defined as a mite density of zero mites per lash. For composite cure, 68% of patients experienced a significant, clinically meaningful cure of both a grade zero or one collarette and erythema score at day 43 compared to 20% on vehicle, with significant improvements seen as early as day 8. Additionally, 13.4% of patients on TP-03 achieved a complete composite cure, which was another secondary endpoint, based on a composite of collarette cure and erythema cure compared to 1.0% on vehicle at day 43. Composite cure is defined as the presence of zero to two collarettes on the upper eyelid and the absence of erythema. Results for complete erythema cure and one grade or more erythema improvement were also statistically significant. TP-03 is a well-characterized anti-parasitic agent that paralyzes and eradicates Demodex mites by selectively inhibiting parasite-specific GABA-Cl channels. Saturn-1 trial results demonstrated that TP-03 was well tolerated with a safety profile similar to the vehicle group. Additionally, most TP-03 patients reported that the drop comfort was neutral to very comfortable. There were no serious treatment-related adverse events nor any treatment-related adverse events leading to treatment discontinuation. All treatment-related ocular adverse events in the TP-03 group were mild with the most common being instillation site pain/burning/stinging. Other adverse events occurring at a rate of greater than or equal to1% in the TP-03 group included instillation site pruritis, reduced visual acuity, eye pain and eye discharge, each representing 1.4% of patients. Tarsus is also evaluating TP-03 in its pivotal Saturn-2 trial, which has the same endpoints as Saturn-1, and commenced patient enrollment in May of 2021. Tarsus expects topline results for the Saturn-2 trial in Q1 2022, and, if the results are similarly positive, Tarsus expects data from both the Saturn-1 and Saturn-2 trials to support submission of a New Drug Application to the FDA for TP-03 for the treatment of Demodex blepharitis.

06:04 EDT GrubHub enters partnership with Resorts World Las Vegas - Resorts World Las Vegas announced a partnership with Grubhub to become the first resort to offer Grubhub's ordering technology. Through On The Fly at Resorts World powered by Grubhub, guests can order and charge the cost to their room or credit card via the Grubhub app from the resort's 40 food and beverage concepts and select retail shops for pickup or delivery to guest rooms as well as the resort's 5.5-acre pool complex.

06:02 EDT KBR awarded NSPA contract for PATRIOT missile system services - KBR was awarded a contract from the NATO Support and Procurement Agency, or NSPA, to provide analytical, engineering, technical, programmatic and logistics services for the PATRIOT missile system. The PATRIOT is an surface-to-air guided air and missile defense system used by several NATO countries around the globe. Under the contract, KBR's work will include systems engineering; program management; modeling and simulation; product assurance; configuration management; production, quality, logistics and deployment; hardware and software integration; field surveillance and test and evaluation. KBR will also conduct studies, engineering evaluations and investigations as requested by NSPA. KBR will primarily carry out its duties at company facilities in Huntsville, Alabama as well as at U.S. government deployment locations worldwide. This contract has a three-year base period and two option years.

05:25 EDT CNH Industrial to acquire Raven for $58.00 per share - CNH Industrial (CNHI) announced that it has entered into an agreement to acquire 100% of the capital stock of Raven (RAVN) for $58.00 per share, representing a 33.6% premium to the Raven Industries four-week volume-weighted average stock price, and $2.1B enterprise value. The transaction will be funded with available cash on hand of CNH Industrial. Closing is expected to occur in Q4, subject to the satisfaction of customary closing conditions, including approval of Raven shareholders and receipt of regulatory approvals. The acquisition builds upon a partnership between the two companies. Headquartered in Sioux Falls, South Dakota, Raven Industries is organized into three business divisions: Applied Technology, Engineered Films and Aerostar with consolidated net sales of $ 348.4M for the twelve months ended January 31. The transaction is expected to generate approximately $400M of run-rate revenue synergies by calendar year 2025, resulting in $150M of incremental EBITDA from synergies. CNH Industrial plans to undertake a strategic review of each business. CNH Industrial does not expect the proposed acquisition will have any impact on its guidance for 2021. The acquisition is expected to be funded with group consolidated cash not affecting third party debt of industrial activities2 Cash consideration for the transaction is not included in the free cash flow definition, and consequently it will not affect its free cash flow guidance for FY21.

05:17 EDT Vaalco Energy appoints Ronald Bain as CFO - Vaalco Energy announced that its board of directors has named Ronald Bain as CFO effective immediately. Bain has over 25 years of oil industry experience in a variety of financial roles and has significant capital markets experience. Bain will be based in the company's recently established London business development office, but he will split his time between London and Houston. Bain is a chartered accountant who was previously CFO at Eland Oil & Gas where he served on that board and a variety of related company Boards until the company was acquired by Seplat Petroleum Development in December 2019.

05:08 EDT Deutsche Bank, Fiserv enter payment acceptance joint venture in Germany - Deutsche Bank (DB) together with Fiserv (FISV) announced a joint venture to create a provider of payment acceptance and banking solutions. The joint venture will serve small and medium-sized enterprises, or SMEs, in the German market and will be based in Frankfurt am Main, pending regulatory approval. This Deutsche Bank and Fiserv joint venture will help SME clients adapt to the changing post-Covid marketplace by equipping them to sell their products and services across a full range of digital and in-person channels using modern payment acceptance solutions, including Clover point-of-sale platform from Fiserv. The companies plan to bring multiple payment solutions together and deliver a combination unique to the market. The joint venture expects to serve several thousand clients from the start. Deutsche Bank, together with their Postbank and Fyrst brands, said it has around 800,000 SMEs who will benefit from the new solutions going forward. The joint venture will also offer services to non-Deutsche Bank-clients and is expected to employ a low triple-digit workforce.